Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Status:
Recruiting
Trial end date:
2023-06-29
Target enrollment:
Participant gender:
Summary
This early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab
work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Giving vemurafenib, cobimetinib, and atezolizumab may work better in
treating high-risk stage III melanoma. Giving atezolizumab and tiragolumab together may also
work better in treating high-risk stage III melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Genentech, Inc. National Cancer Institute (NCI) Stand Up To Cancer